Eye implant could replace daily drops for glaucoma

NCT ID NCT06964191

Ongoing Disease control Sponsor: PolyActiva Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This clinical trial tests an implant called PA5108 that is placed inside the eye to lower pressure in adults with open-angle glaucoma or ocular hypertension. The implant is compared to standard latanoprost eye drops. The study aims to find the right dose that is both safe and effective at reducing eye pressure over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PA5108 Ocular Implant
What this could lead to: If it works, this implant could offer a long-lasting alternative to daily eye drops for controlling eye pressure in glaucoma patients.
What could go wrong: This is an early phase 2 trial with only 75 participants, so results may not apply broadly. Risks include eye irritation, infection, or damage to corneal cells.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLAUCOMA, OPEN-ANGLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLAUCOMA, OPEN-ANGLE OCULAR HYPERTENSION

Contacts and locations

Show contact details

Locations

Eye Research Foundation

Newport Beach, California, 92663, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.